Myriad Genetics, Inc (NASDAQ:MYGN) currently has a daily average trading volume of 1.91M but it saw 2310996 shares traded in last market. With a market cap of 362.26M USD, the company’s current market price of $3.93 came falling about -3.44 while comparing to the previous closing price of $4.07. In past 52 weeks, the stock remained buoying in the range of price level as high as $29.30 and as low as $3.81.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Scotiabank which downgraded the stock as “Sector Perform” in its note to investors issued on May 21, 2025, recommending a price target of $6 for it. Wells Fargo also issued its recommendations for the stock as it downgraded the price target for the stock is $6.
Over the week, MYGN’s stock price is moving -4.38% down while it is -46.09% when we observe its performance for the past one month. Year-to-date it is -71.33% down and over the past year, the stock is showing a downside performance of -84.29%.
Currently, Myriad Genetics, Inc’s total number of outstanding shares is 92.20M with 2.36% of that held by the insiders while 104.65% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -11.91% and return on equity (ROE) at -13.84%. It has a 25.19 of forward P/E ratio. Stock’s beta reads 1.89. Stock has a price to book (P/B) ratio of 0.51 while price to sale or P/S ratio amounts to 0.44. Its return on asset (ROA) is -9.58% on average.
